<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Challenges in modern medicine</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.52575/2687-0940-2024-47-1-5-13</article-id><article-id pub-id-type="publisher-id">178</article-id><article-categories><subj-group subj-group-type="heading"><subject>INTERNAL DISEASES</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Pompe Disease with a Late Onset. What Does a Practitioner Need to Know About?&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Pompe Disease with a Late Onset. What Does a Practitioner Need to Know About?&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Vishnevskij</surname><given-names>Valery I.</given-names></name><name xml:lang="en"><surname>Vishnevskij</surname><given-names>Valery I.</given-names></name></name-alternatives><email>vishnevsky.orel@mail.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Ternovykh</surname><given-names>Tatiana V.</given-names></name><name xml:lang="en"><surname>Ternovykh</surname><given-names>Tatiana V.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Melnikova</surname><given-names>Evgenia A.</given-names></name><name xml:lang="en"><surname>Melnikova</surname><given-names>Evgenia A.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Panina</surname><given-names>Yulia N.</given-names></name><name xml:lang="en"><surname>Panina</surname><given-names>Yulia N.</given-names></name></name-alternatives><email>doc.panina@yandex.ru</email></contrib></contrib-group><pub-date pub-type="epub"><year>2024</year></pub-date><volume>47</volume><issue>1</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2024/1/АПМ_2024_5-13.pdf" /><abstract xml:lang="ru"><p>The article presents a clinical case of observation and treatment of a patient with late-onset Pompe disease (LОPD), a rare hereditary storage disease associated with a deficiency of the enzyme acid maltase (acid &amp;alpha;-glucosidase) in lysosomes. The first signs of the disease in patient S. &amp;ndash; recurrent abdominal pain &amp;ndash; appeared at the age of 10. The diagnosis of late-onset Pompe disease was made in one of the federal centers after careful laboratory and molecular genetic studies. Enzyme replacement therapy with Alglucosidase Alpha gave positive results: the patient&amp;#39;s condition stabilized, the activity of a number of indicators decreased &amp;ndash; aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK). The presented proven clinical case of late-onset Pompe disease with an assessment of the patient&amp;rsquo;s condition before treatment and the results after enzyme replacement therapy can be useful in the practical work of a wide range of doctors - internists, gastroenterologists, neurologists, general practitioners, etc.</p></abstract><trans-abstract xml:lang="en"><p>The article presents a clinical case of observation and treatment of a patient with late-onset Pompe disease (LОPD), a rare hereditary storage disease associated with a deficiency of the enzyme acid maltase (acid &amp;alpha;-glucosidase) in lysosomes. The first signs of the disease in patient S. &amp;ndash; recurrent abdominal pain &amp;ndash; appeared at the age of 10. The diagnosis of late-onset Pompe disease was made in one of the federal centers after careful laboratory and molecular genetic studies. Enzyme replacement therapy with Alglucosidase Alpha gave positive results: the patient&amp;#39;s condition stabilized, the activity of a number of indicators decreased &amp;ndash; aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK). The presented proven clinical case of late-onset Pompe disease with an assessment of the patient&amp;rsquo;s condition before treatment and the results after enzyme replacement therapy can be useful in the practical work of a wide range of doctors - internists, gastroenterologists, neurologists, general practitioners, etc.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Pompe disease</kwd><kwd>late-onset Pompe disease</kwd><kwd>acid α-glucosidase</kwd><kwd>enzyme replacement therapy</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Pompe disease</kwd><kwd>late-onset Pompe disease</kwd><kwd>acid α-glucosidase</kwd><kwd>enzyme replacement therapy</kwd></kwd-group></article-meta></front><back><ack><p>The work was carried out without external sources of funding.</p></ack><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Kurbatov S.A., Nikitin S.S., Zaharova E.Yu. 2015. Bolezn&amp;#39; Pompe s pozdnim nachalom c fenotipom poyasno-konechnostnoj miodistrofii [Late-Onset Pompe Disease with Girdle-Bone Myodystrophy Phenotype]. Nervno-myshechnye bolezni 5(3): 62&amp;ndash;8. doi: 10.17650/2222-8721-2015-5-3-6268.Sun A. 2018. Lysosomal storage disease overview. Ann Transl Med. 6:476. doi: 10.21037/atm.2018.11.39</mixed-citation></ref><ref id="B2"><mixed-citation>Sun A. 2018. Lysosomal Storage Disease Overview. Ann Transl Med. 6: 476. doi: 10.21037/atm.2018.11.39</mixed-citation></ref><ref id="B3"><mixed-citation>de Araujo M.E., Liebscher G., Hess M.W., Huber L.A. 2020. Lysosomal Size Matters. Traffic.; 21: 60&amp;ndash;75. doi: 10.1111/tra.12714</mixed-citation></ref><ref id="B4"><mixed-citation>Heffner G., James L., Chaivorapol C. 2018. A Novel Hybrid Promote Directing AAV-Mediated Expression of Acid Alpha-Glucosidase to Liver, Muscle and CNS Yields Optimized Outcomes in a Mouse Model of Pompe Disease.&amp;nbsp;Neuromuscular Disord. 28: S135-6.</mixed-citation></ref><ref id="B5"><mixed-citation>Martina J.A., Raben N., Puertollano R. 2020. Lysosomal Storage Diseases.&amp;nbsp;Cell. 180:602&amp;ndash;02.e1. doi: 10.1016/j.cell.2020.01.017</mixed-citation></ref><ref id="B6"><mixed-citation>Pena L.D., Barohn R., Byrne B. 2019. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of the Novel Enzyme Replacement Therapy Avalglucosidase Alfa (neoGAA) in Treatment-Na&amp;iuml;ve and Alglucosidase Alfa-Treated Patients with Late-Onset Pompe Disease: A Phase 1, Open-Label, Multicenter, Multinational, Ascending Dose Study; 29: 167&amp;ndash;86. doi:&amp;nbsp;10.1016/j.nmd.2018.12.004</mixed-citation></ref><ref id="B7"><mixed-citation>Clemens P., Mozaffar T., Schoser B. 2019. Safety and Efficacy of Advanced and Targeted Acid &amp;alpha;-glucosidase (AT-GAA)(ATB200/AT2221) in ERT-switch Nonambulatory Patients with Pompe Disease: Preliminary Results from the ATB200-02 Trial. Mol. Genet. Metab. 126: S40-1. doi:10.1016/j.ymgme.2018.12.084</mixed-citation></ref><ref id="B8"><mixed-citation>Kishnani P., Schoser B., Bratkovic D. 2019. First-in-human Study of Advanced and Targeted Acid &amp;alpha;-glucosidase (AT-GAA) (ATB200/AT2221) in Patients with Pompe Disease: Preliminary Functional Assessment Results from the ATB200-02 Trial. Mol. Genet. Metab. 126: S86. doi:10.1016/j.ymgme.2018.12.212</mixed-citation></ref><ref id="B9"><mixed-citation>Hardcastle N., Boulis N.M., Federici T. 2018.&amp;nbsp;AAV Gene Delivery to the Spinal Cord: Serotypes, Methods, Candidate Diseases, and Clinical Trials.&amp;nbsp;Expert Opin. Biol. Ther. 18: 293&amp;ndash;307. doi:&amp;nbsp;10.1080/14712598.2018.1416089</mixed-citation></ref><ref id="B10"><mixed-citation>Keeler A.M., Zieger M., Todeasa S.H. 2019. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.&amp;nbsp;Hum Gene Ther 30: 57&amp;ndash;68. doi:&amp;nbsp;10.1089/hum.2018.016</mixed-citation></ref><ref id="B11"><mixed-citation>Kohler L., Puertollano R., Raben N. 2018. Pompe Disease: From Basic Science to Therapy.&amp;nbsp;Neurotherapeutics 15: 928&amp;ndash;42 doi:&amp;nbsp;10.1007/s13311-018-0655-y</mixed-citation></ref><ref id="B12"><mixed-citation>Mayeuf-Louchart A., Lancel S., Sebti Y., Pourcet B., Loyens A., Delhaye S., Duhem C., Beauchamp J., Ferri L., Thorel Q., Boulinguiez A., Zecchin M., Dubois-Chevalier J. 2019. Glycogen Dynamics Drives Lipid Droplet Biogenesis During Brown Adipocyte Differentiation. Cell Rep.; 29: 1410&amp;ndash;18. e6. doi: 10.1016/j.celrep.2019.09.073</mixed-citation></ref><ref id="B13"><mixed-citation>Gupta N., Kazi Z.B., Nampoothiri S., Jagdeesh S., Kabra M., Puri R.D., Muranjan M., Kalaivani M., Rehder C., Bali D., Verma I.C., Kishnani P.S. 2020.&amp;nbsp;Clinical and Molecular Disease Spectrum and Outcomes in Patients with Infantile-Onset Pompe Disease.&amp;nbsp;J Pediatr. 216: 44&amp;ndash;50. e5. doi: 10.1016/j.jpeds.2019.08.058</mixed-citation></ref><ref id="B14"><mixed-citation>Ellingwood S.S., Cheng A. 2018. Biochemical and clinical aspects of glycogen storage diseases.&amp;nbsp;J. Endocrinol. Sep; 238(3): R131-R141, &amp;nbsp;doi:&amp;nbsp;10.1530/JOE-18-0120</mixed-citation></ref><ref id="B15"><mixed-citation>Reuser A.J., van der Ploeg A.T., Chien Y.H., Llerena J. Jr., Abbott M.A., Clemens P.R., Kimonis V.E., Leslie N., Maruti S.S., Sanson B.J., Araujo R., Periquet M., Toscano A. 2019. GAA Variants and Phenotypes Among 1,079 Patients with Pompe Disease: Data from the Pompe Registry. 40: 2146&amp;ndash;64. doi: 10.1002/humu.23878</mixed-citation></ref><ref id="B16"><mixed-citation>Skurat A.V., Segvich D.M., De Paoli-Roach A.A., Roach P.J.&amp;nbsp;2017. Novel Method for Detection of Glycogen in Cells.&amp;nbsp;Glycobiology; 27(5): 416&amp;ndash;424. doi: 10.1093/glycob/cwx005</mixed-citation></ref><ref id="B17"><mixed-citation>Rodrigues G.A., Shalaev E., Karami T.K. 2018. Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye. Pharm. Res. 36: 29. doi:&amp;nbsp;10.1007/s11095-018-2554-7</mixed-citation></ref><ref id="B18"><mixed-citation>Boentert M., Prigent H., V&amp;aacute;rdi K. 2016. Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe disease. Int. J. Mol. Sci. 17: 1&amp;ndash;17. doi: 10.3390/ijms17101735</mixed-citation></ref><ref id="B19"><mixed-citation>Chan J., Kazi Z.B., Desai A.K. 2017. The Emerging Phenotype of Late-Onset Pompe Disease: a Systematic Literature Review. Mol. Genet. Metab; 120(3): 163&amp;ndash;72. doi: 10.1016/ j.ymgme. 2016.12.004.</mixed-citation></ref><ref id="B20"><mixed-citation>Park H., Kim J., Lee Y.K. 2018. Four Unreported Types of Glycans Containing Mannose-6-Phosphate are Heterogeneously Attached at Three Sites (Including Newly Found Asn 233) to Recombinant Human Acid Alpha-Glucosidase that is the Only Approved Treatment for Pompe Disease. Biochem. Biophys. Res. Commun. 495: 2418&amp;ndash;24. doi:&amp;nbsp;10.1016/j.bbrc.2017.12.101</mixed-citation></ref><ref id="B21"><mixed-citation>Poelman E., Hoogeveen-Westerveld M., Kroos-de Haan M.A. 2018. High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy. J. Pediatr. 195: 236&amp;ndash;43. e3. doi:&amp;nbsp;10.1016/j.jpeds.2017.11.046</mixed-citation></ref><ref id="B22"><mixed-citation>Toscano A., Rodolico C., Musumeci O. 2019. Multisystem Late Onset Pompe Disease (LOPD): an Update on Clinical Aspects. 7: 284. doi: 10.21037/atm.2019.07.24</mixed-citation></ref><ref id="B23"><mixed-citation>Tarallo A., Carissimo A., Gatto F., Nusco E., Toscano A., Musumeci O., Coletta M., Karali M., Acampora E., Damiano C., Minopoli N., Fecarotta S., Della Casa R. 2019.&amp;nbsp; MicroRNAs as Biomarkers in Pompe Disease.&amp;nbsp;Genet Med. 21: 591&amp;ndash;600. doi: 10.1038/s41436-018-0103-8</mixed-citation></ref></ref-list></back></article>